Oramed Pharmaceuticals (ORMP) Current Deferred Revenue (2015 - 2026)

Oramed Pharmaceuticals' Current Deferred Revenue history runs 11 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• Quarterly Current Deferred Revenue changed N/A year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (changed N/A YoY) and the FY2025 annual result came in at $1.3 million, changed N/A from the prior year.
• Current Deferred Revenue was $1.5 million for Q1 2026 at Oramed Pharmaceuticals, up from $1.3 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $2.7 million in Q1 2022 and bottomed at $674000.0 in Q1 2023.
• A 4-year average of $1.5 million and a median of $1.3 million in 2022 frame the typical range for Current Deferred Revenue.
• Peak annual rise in Current Deferred Revenue reached 75.06% in 2023, while the deepest fall reached 75.06% in 2023.
• Oramed Pharmaceuticals' Current Deferred Revenue stood at $1.3 million in 2022, then tumbled by 49.7% to $674000.0 in 2023, then jumped by 88.28% to $1.3 million in 2025, then advanced by 15.92% to $1.5 million in 2026.
• Business Quant data shows ORMP's Current Deferred Revenue at $1.5 million in Q1 2026, $1.3 million in Q4 2025, and $986000.0 in Q3 2025.